Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Modified Short-Course Radiotherapy Combined With Tislelizumab, CAPOX Chemotherapy and Bevacizumab as First-Line Treatment for Initially Unresectable Microsatellite Stable Metastatic Colorectal Cancer

NCT07512674 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07512674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07512674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Modified Short-Course Radiotherapy Combined With Tislelizumab, CAPOX Chemotherapy and Bevacizumab as First-Line Treatment for Initially Unresectable Microsatellite Stable Metastatic Colorectal Cancer
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 26, 2026
Completion date
March 31, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with initially unresectable mss-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis